| Cat. No. | Product Name | Field of Application | Chemical Structure |
|---|---|---|---|
| DC8768 | HMN-214 Featured | HMN-214(IVX214) is a potent PLK1 inhibitor an average IC50 of 0.12 μM. |
|
| DC9697 | HUHS015 Featured | HUHS015 is a prostate cancer antigen (PCA)-1/AlkB homologue 3 (ALKBH3) inhibitor. |
|
| DC9614 | Hydroxyfasudil (hydrochloride) Featured | Hydroxyfasudil Hcl(HA1100 Hcl), metabolite of Fasudil, is a potent Rho-kinase inhibitor and vasodilator. |
|
| DC11303 | CT7001 hydrochloride Featured | ICEC0942 is a selective CDK7 inhibitor, with IC50s of 41 nM and 578 nM for CDK7/CycH/MAT1 and CDK2/cycE1, respectively. |
|
| DC8111 | Idarubicin Hydrochloride Featured | Idarubicin Hcl is an anthracycline antibiotic and a DNA topoisomerase II (topo II) inhibitor. |
.gif)
|
| DC9014 | Ifosfamide | Ifosfamide is a nitrogen mustard alkylating agent used in the treatment of cancer. |
|
| DC12310 | INH154 | INH154 is a highly potent inhibitor for Nek2 and Hec1 binding (INH), with IC50s of 200 nM and 120 nM for INH in Hela and MB468 cells. |
|
| DC7641 | INH6 Featured | INH6 is a potent Hec1 inhibitor, which specifically disrupts the Hec1/Nek2 interaction and causes chromosome mis-alignment. |
|
| DC4153 | Irinotecan hydrochloride trihydrate | Irinotecan prevents DNA from unwinding by inhibition of topoisomerase 1. |
|
| DC8934 | Irinotecan Featured | Irinotecan(CPT-11) prevents DNA from unwinding by inhibition of topoisomerase 1. |
|
| DC7431 | ISRIB Featured | ISRIB (trans-isomer), the trans-isomer of ISRIB, is a potent and selective PERK inhibitor with IC50 of 5 nM. |
|
| DC7178 | JNJ-7706621 Featured | JNJ-7706621 is pan-CDK inhibitor with the highest potency on CDK1/2 with IC50 of 9 nM/4 nM and showing >6-fold selectivity for CDK1/2 than CDK3/4/6; also potently inhibits Aurora A/B and has no activity on Plk1 and Wee1. |
|
| DC11080 | JPI-289 | JPI-289 (JPI289) is a novel potent, water soluble PARP-1 inhibitor with IC50 of 18.5 nM, inhibits cellular PAR formation with IC50 of 10.7 nM. |
|
| DC7169 | JW55 Featured | JW 55 is an inhibitor of the PARP domain of tankyrase 1 and 2 (TNKS1/2). JW55 decreased auto-PARsylation of TNKS1/2 in vitro with IC50 values of 1.9 uM and 830 nM respectively. |
|
| DC7774 | Ripasudil(K-115) Featured | K-115, an isoquinolinesulfonamide compound, is a highly selective and potent (IC50 = 31 nM) Rho-kinase inhibitor; is in Phase II clinical development in patients with POAG or ocular hypertension. |
|
| DC7871 | KCL-440 | KCL-440 is a a new poly(ADP-ribose) polymerase- PARP inhibitor. |
|
| DC5093 | NSC-664704(Kenpaullone) Featured | Kenpaullone is an ATP-competitive inhibitor of several cyclin-dependent kinases (CDKs) as well as glycogen synthase kinase 3β (GSK3β). |
|
| DC3113 | KU-0060648 Featured | KU 0060648 is a potent and selective inhibitor of DNA-dependent protein kinase (DNA-PK), (IC50 = 8.6 nM); with 20-1000 fold selectivity for DNA-PK over other PIKKs and a panel of 60 kinases. |
|
| DC1067 | KU-55933 Featured | KU-55933 is a potent and specific ATM inhibitor with IC50 and Ki of 13 nM and 2.2 nM, respectively. |
|
| DC7448 | KU-60019 Featured | KU-60019 is an improved analogue of KU-55933, with IC50 of 6.3 nM for ATM. |
|
| DC9394 | LDC000067 Featured | LDC000067(LDC-067) is a highly specific CDK9 inhibitor with IC50 of 32.7 nM for CDK9/cyclin T1; displays 55/125/210/ >227/ >227-fold selectivity for CDK9 versus CDK2/1/4/6/7. |
|
| DC10143 | LDC-4297 Featured | LDC4297 is a novel CDK7 inhibitor. |
|
| DC9773 | LEE011 hydrochloride Featured | LEE011 Hcl is an orally available cyclin-dependent kinase (CDK) inhibitor targeting cyclin D1/CDK4 and cyclin D3/CDK6 cell cycle pathway, with potential antineoplastic activity. |
|
| DC7453 | Ribociclib (LEE011) Featured | LEE011 is an orally available cyclin-dependent kinase (CDK) inhibitor targeting cyclin D1/CDK4 and cyclin D3/CDK6 cell cycle pathway, with potential antineoplastic activity. |
|
| DC9774 | LEE011 succinate Featured | LEE011 succinate is an orally available cyclin-dependent kinase (CDK) inhibitor targeting cyclin D1/CDK4 and cyclin D3/CDK6 cell cycle pathway, with potential antineoplastic activity. |
.gif)
|
| DC7103 | LY2603618(IC-83) Featured | LY2603618(IC-83) is a potent and selective small molecule inhibitor of Chk1 protein kinase activity in vitro (IC50=7 nM) and the first selective Chk1 inhibitor to enter clinical cancer trials. |
|
| DC7993 | Prexasertib (LY2606368) 2HCl Featured | LY2606368 2Hcl is a potent and selective ATP competitive inhibitor(IC50=1.5 nM in SW1990 cell) of the Chk1 protein kinase. |
|
| DC10796 | Prexasertib (LY2606368) Featured | LY2606368 is a potent and selective ATP competitive inhibitor(IC50=1.5 nM in SW1990 cell) of the Chk1 protein kinase. |
|
| DC8643 | LY2835219 free base (Abemaciclib) Featured | LY2835219 is an orally available cyclin-dependent kinase (CDK) inhibitor that targets the CDK4 (cyclin D1) and CDK6 (cyclin D3) cell cycle pathway, with potential antineoplastic activity. |
|
| DC5062 | LY2835219(Abemaciclib) Featured | LY2835219 is an orally available cyclin-dependent kinase (CDK) inhibitor that targets the CDK4 (cyclin D1) and CDK6 (cyclin D3) cell cycle pathway, with potential antineoplastic activity. |
|
